Headache

Article	Citations
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice	292
COVID‐19 is a Real Headache!	178
The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic‐specific estimates from government health surveys	124
Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review	98
The Role of Diet and Nutrition in Migraine Triggers and Treatment: A Systematic Literature Review	87
Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine	83
Headaches During COVID‐19: My Clinical Case and Review of the Literature	72
Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study	71
Headache as a Cardinal Symptom of Coronavirus Disease 2019: A Cross‐Sectional Study	63
Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study	63
Hypertension: A new safety risk for patients treated with erenumab	61
Dual Therapy With Anti‐CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?	58
Spectrum of Headaches Associated With SARS‐CoV‐2 Infection: Study of Healthcare Professionals	56
High Prevalence of Headaches During Covid‐19 Infection: A Retrospective Cohort Study	56
Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine	56
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication‐overuse headache: Subgroup analysis of PROMISE‐2	55
COVID‐19 and Headache: A Primer for Trainees	54
Case Series of Headache Characteristics in COVID‐19: Headache Can Be an Isolated Symptom	52
Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study	52
Chronic versus episodic migraine: The 15‐day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency	47
Persistent Headache and Persistent Anosmia Associated With COVID‐19	45
Frequency and Type of Red Flags in Patients With Covid‐19 and Headache: A Series of 104 Hospitalized Patients	43
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study	42
Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study	42
Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients	42

Headache associated with COVID‐19: Epidemiology, characteristics, pathophysiology, and management	40
Toward a better understanding of persistent headache after mild COVID‐19: Three migraine‐like yet distinct scenarios	40
The Effect of Psychiatric Comorbidities on Headache‐Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study	40
Headache attributed to idiopathic intracranial hypertension and persistent post‐idiopathic intracranial hypertension headache: A narrative review	38
Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1	38
Cluster headache is one of the most intensely painful human conditions: Results from the International Cluster Headache Questionnaire	37
Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients	36
Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study	36
Erenumab for headaches in idiopathic intracranial hypertension: A prospective open‐label evaluation	35
Remote electrical neuromodulation for acute treatment of migraine in adolescents	34
Erenumab in Chronic Migraine: An Australian Experience	34
Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing	33
Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial	33
Efficacy and Contextual (Placebo) Effects of CGRP Antibodies for Migraine: Systematic Review and Meta‐analysis	32
Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study	32
Headache characteristics and burden from chronic migraine with medication overuse headache: Cross‐sectional observations from the Medication Overuse Treatment Strategy trial	30
A link between gastrointestinal disorders and migraine: Insights into the gut–brain connection	30
Neck pain associated with migraine does not necessarily reflect cervical musculoskeletal dysfunction	29
Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data	29
Systematic review of outcomes and endpoints in preventive migraine clinical trials	28
Smartphone‐Delivered Progressive Muscle Relaxation for the Treatment of Migraine in Primary Care: A Randomized Controlled Trial	28
Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study	27
Headache in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Narrative Review	26
Cognitive Networks Disarrangement in Patients With Migraine Predicts Cutaneous Allodynia	26
Real‐world efficacy, tolerability, and safety of ubrogepant	26
Systematic review of outcomes and endpoints in acute migraine clinical trials	25
Learning the full impact of migraine through patient voices: A qualitative study	25
Migraine as a Cortical Brain Disorder	25
Trigeminal neuralgia as the sole neurological manifestation of COVID‐19: A case report	25
Management of primary headaches during pregnancy, postpartum, and breastfeeding: A systematic review	25
Patient experience of telemedicine for headache care during the COVID‐19 pandemic: An American Migraine Foundation survey study	25
Headache in transgender and gender‐diverse patients: A narrative review	25
Spontaneous spinal cerebrospinal fluid‐venous fistulas in patients with orthostatic headaches and normal conventional brain and spine imaging	24
Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT‐6) Total and Item‐Specific Scores in Chronic Migraine	23
United States Patients’ Perspective of Living With Migraine: Country‐Specific Results From the Global “My Migraine Voice” Survey	23
Understanding the migraine treatment landscape prior to the introduction of calcitonin gene‐related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patien	23
Serum Homocysteine, Pyridoxine, Folate, and Vitamin B12 Levels in Migraine: Systematic Review and Meta‐Analysis	23
Visual snow syndrome, the spectrum of perceptual disorders, and migraine as a common risk factor: A narrative review	22
Dietary magnesium and migraine in adults: A cross‐sectional analysis of the National Health and Nutrition Examination Survey 2001–2004	22
Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double‐Blind, Placebo‐Controlled REGAI	22
Impact of Depression and Anxiety Symptoms on Patient‐Reported Outcomes in Patients With Migraine: Results From the American Registry for Migraine Research (ARMR)	22
Indomethacin‐responsive headaches—A narrative review	22
Cranial Autonomic Symptoms of Migraine in Japan: Prospective Study of 373 Migraine Patients at a Tertiary Headache Center	22
63rd Annual Scientific Meeting American Headache Society®	22
Patient‐identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient‐centered outcome	21
Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication‐overuse headache	21
Cyclic vomiting syndrome: A narrative review and guide to management	21
Alterations in Functional Connectivity During Different Phases of the Triggered Migraine Attack	21
Could CGRP Antagonists Be Helpful in the Fight Against COVID‐19?	21
Phase 2 randomized placebo‐controlled study of lasmiditan for the acute treatment of migraine in Japanese patients	20

No “Wearing‐Off Effect” Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long‐Term Study	20
Characterization of chronic overlapping pain conditions in patients with chronic migraine: A CHOIR study	20
Trigeminal Neuralgia Crisis – Intravenous Phenytoin as Acute Rescue Treatment	19
The changing face of trigeminal neuralgia—A narrative review	18
Green Flags and headache: A concept study using the Delphi method	18
The Stereotypical Image of a Person With Migraine According to Mass Media	18
Headache education by leaflet distribution during COVID‐19 vaccination and school‐based on‐demand e‐learning: Itoigawa Geopark Headache Awareness Campaign	18
What are Headache Smartphone Application (App) Users Actually Looking for in Apps: A Qualitative Analysis of App Reviews to Determine a Patient Centered Approach to Headache Smartphone Apps	18
Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trial	18
A Randomized, Double‐Dummy, Emergency Department‐Based Study of Greater Occipital Nerve Block With Bupivacaine vs Intravenous Metoclopramide for Treatment of Migraine	18
Acceptance and commitment therapy for high frequency episodic migraine without aura: Findings from a randomized pilot investigation	18
Early impact of the COVID‐19 pandemic on outpatient migraine care in Hawaii: Results of a quality improvement survey	18
COVID‐19 and Headache Medicine: A Narrative Review of Non‐Steroidal Anti‐Inflammatory Drug (NSAID) and Corticosteroid Use	17
Alterations in the structure and function of the brain in adolescents with new daily persistent headache: A pilot MRI study	17
Delay in OnabotulinumtoxinA Treatment During the COVID‐19 Pandemic‐Perspectives from a Virus Hotspot	17
Serum lipid abnormalities in migraine: A meta‐analysis of observational studies	17
Headache as the Presenting Symptom in 2 Patients With COVID‐19 and a History of Migraine: 2 Case Reports	17
Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real‐World Case Series	16
Melatonin for Acute Treatment of Migraine in Children and Adolescents: A Pilot Randomized Trial	16
Prevalence and association of lifestyle and medical‐, psychiatric‐, and pain‐related comorbidities in patients with migraine: A cross‐sectional study	16
Are Migraine Patients at Increased Risk for Symptomatic Coronavirus Disease 2019 Due to Shared Comorbidities?	16
Epidemiology, investigation, management, and outcome of headache in emergency departments (HEAD study)—A multinational observational study	16
Risk of Acute Myocardial Infarction, Heart Failure, and Death in Migraine Patients Treated with Triptans	15
Patterns of Perceived Stress Throughout the Migraine Cycle: A Longitudinal Cohort Study Using Daily Prospective Diary Data	15
Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis	15
Psychometric validation and meaningful within‐patient change of the Migraine‐Specific Quality of Life questionnaire version 2.1 electronic patient‐reported outcome in patients with episodic and chroni	15
Telehealth as a new care delivery model: The headache provider experience	15
Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans	15
Diagnostic accuracy of an artificial intelligence online engine in migraine: A multi‐center study	15
A non‐convulsant delta‐opioid receptor agonist, KNT‐127, reduces cortical spreading depression and nitroglycerin‐induced allodynia	15
Trigeminal and cervical sensitization during the four phases of the migraine cycle in patients with episodic migraine	15
Cluster headache epidemiology including pediatric onset, sex, and ICHD criteria: Results from the International Cluster Headache Questionnaire	14
What Will it Take to Move the Needle for Headache Disorders? An Advocacy Perspective	14
Normal glymphatic system function in patients with migraine: A pilot study	14
Telehealth perceptions and utilization for the delivery of headache care before and during the COVID‐19 pandemic: A mixed‐methods study	14
Evidence that blood–CSF barrier transport, but not inflammatory biomarkers, change in migraine, while CSF sVCAM1 associates with migraine frequency and CSF fibrinogen	14
The intersection of COVID‐19, school, and headaches: Problems and solutions	14
A Real‐World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment	14
The endocannabinoid system and related lipids as potential targets for the treatment of migraine‐related pain	14
A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene‐related peptide and beyond	13
Clinical features of new daily persistent headache: A retrospective chart review of 328 cases	13
STOP 301: A Phase 3, open‐label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acu	13
Migraine and Sport in a Physically Active Population of Students: Results of a Cross‐Sectional Study	13
Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine	13
Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine	13
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice	13
The Effect of Adding Calcitonin Gene‐Related Peptide Monoclonal Antibodies to Onabotulinum Toxin A Therapy on Headache Burden: A Retrospective Observational Case Series	13
Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial	13
Triggers of Primary Headaches: Issues and Pathways Forward	13
Impact of abuse on migraine‐related sensory hypersensitivity symptoms: Results from the American Registry for Migraine Research	13
Migraine and light: A narrative review	13
Perceived stress and pain severity in individuals with chronic migraine: A longitudinal cohort study using daily prospective diary data	13
Primary headaches among gender dysphoric female‐to‐male individuals: A cross‐sectional survey on gender transition experience	13
Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study	13
A new hypothesis linking oxytocin to menstrual migraine	12
Arachnoiditis, a complication of epidural blood patch for the treatment of low‐pressure headache: A case report and systematic review	12
E‐Consultation in Headache Medicine: A Quality Improvement Pilot Study	12
Employee and Employer Benefits From a Migraine Management Program: Disease Outcomes and Cost Analysis	12
Headache as a COVID‐19 onset symptom and post‐COVID‐19 symptom in hospitalized COVID‐19 survivors infected with the Wuhan, Alpha, or Delta SARS‐CoV‐2 varian	12
Migraine diagnosis and treatment: A knowledge and needs assessment of women’s healthcare providers	12
Stimulation of Posterior Thalamic Nuclei Induces Photophobic Behavior in Mice	12
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response	12
The relationship of headache as a symptom to COVID‐19 survival: A systematic review and meta‐analysis of survival of 43,169 inpatients with COVID‐19	12
Objectively Measured Physical Activity in Migraine as a Function of Headache Activity	12
The current state of headache medicine education in the United States and Canada: An observational, survey‐based study of neurology clerkship directors and curriculum deans	12
Development and Internal Validation of a Multivariable Prediction Model for Individual Episodic Migraine Attacks Based on Daily Trigger Exposures	12
Validity and reliability of the self‐administered Visual Aura Rating Scale questionnaire for migraine with aura diagnosis: A prospective clinic‐based study	12
Dietary zinc intake and migraine in adults: a cross‐sectional analysis of the National Health and Nutrition Examination Survey 1999–2004	12
Development and validation of a novel patient‐reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary	11
Measurement properties of the Headache Impact Test (HIT‐6™ Brazil) in primary and secondary headaches	11
Wear‐Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries	11
The Health and Productivity Burden of Migraines in Australia	11
Patients With Vestibular Migraine are More Likely to Have Occipital Headaches than those With Migraine Without Vestibular Symptoms	11
Evaluation of 2‐Hour Post‐Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult‐to‐Treat Migraine Attacks	11
Allodynia and Disability in Migraine: The Mediating Role of Stress	11
Baseline sleep quality, stress, and depressive symptoms, and subsequent headache occurrence in a six‐week prospective cohort study of patients with episodic migraine	11
Narrative review of peripheral nerve blocks for the management of headache	11
Migraine with aura associates with a higher artificial intelligence: ECG atrial fibrillation prediction model output compared to migraine without aura in both women and men	11
Calcitonin Gene‐Related Peptide Receptor Antagonists (Gepants) for the Acute Treatment of Nausea in Episodic Migraine: A Systematic Review and Meta‐Analysis	11
Investigating the effects of weather on headache occurrence using a smartphone application and artificial intelligence: A retrospective observational cross‐sectional study	11

Headache response after CT‐guided fibrin glue occlusion of CSF‐venous fistulas	11
Erenumab patient characteristics, medication adherence, and treatment patterns in the United States	11
Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment	10
62nd Annual Scientific Meeting American Headache Society®	10
The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review	10
Impact of the COVID‐19 pandemic on people living with migraine: Results of the MiCOAS qualitative study	10
Prolactin signaling modulates stress‐induced behavioral responses in a preclinical mouse model of migraine	10
Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study	10
Remote electrical neuromodulation for migraine prevention: A double‐blind, randomized, placebo‐controlled clinical trial	10
Real‐world assessment of the relationship between migraine‐related disability and healthcare costs in the United States	10
The role of avoiding known triggers, embracing protectors, and adhering to healthy lifestyle recommendations in migraine prophylaxis: Insights from a prospective cohort of 1125 people with episodic mi	10
Characteristics and natural disease history of persistent idiopathic facial pain, trigeminal neuralgia, and neuropathic facial pain	10
Changes in migraine characteristics over 30 days of Ramadan fasting: A prospective study	9
American Headache Society 64th Annual Scientific Meeting June 9–12, 2022 Denver, Colorado	9
Effectiveness of manual therapy in the treatment of cervicogenic headache: A systematic review	9
Prospective cohort study of routine exercise and headache outcomes among adults with episodic migraine	9
Dietary intake of thiamine and riboflavin in relation to severe headache or migraine: A cross‐sectional survey	9
Does “wearing off” of efficacy occur in galcanezumab‐treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials	9
A real‐world, observational study of erenumab for migraine prevention in Canadian patients	9
Migraine and peripheral pain models show differential alterations in neuronal complexity	9
Are psychological interventions efficacious for adults with migraine? A systematic review and meta‐analysis	9
Ten Eleven things to facilitate participation of underrepresented groups in headache medicine research	9
Structural aberrations of the brain associated with migraine: A narrative review	9
Migraine and balance impairment: Influence of subdiagnosis, otoneurological function, falls, and psychosocial factors	9
Migraine treatment with external concurrent occipital and trigeminal neurostimulation—A randomized controlled trial	9
Association among headache, temporomandibular disorder, and awake bruxism: A cross‐sectional study	9
Understanding What People With Migraine Consider to be Important Features of Migraine Tracking: An Analysis of the Utilization of Smartphone‐Based Migraine Tracking With a Free‐Text Feature	9
An observational study of self‐reported migraine triggers and prospective evaluation of the relationships with occurrence of attacks enabled by a smartphone application (App)	9
Trigeminal neuralgia in children and adolescents: Experience of a tertiary pediatric headache clinic	9
The association between inflammatory bowel disease and migraine or severe headache among US adults: Findings from the National Health Interview Survey, 2015‐2016	9
Headache persisting after aneurysmal subarachnoid hemorrhage: A narrative review of pathophysiology and therapeutic strategies	9
Longitudinal Impact of Parent Factors in Adolescents With Migraine and Tension‐Type Headache	9
Cluster headache pathophysiology: What we have learned from advanced neuroimaging	9
Efficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: Case series and narrative review	9
“You will eat shoe polish if you think it would help”—Familiar and lesser‐known themes identified from mixed‐methods analysis of a cluster headache survey	8
Challenges and complexities in designing cluster headache prevention clinical trials: A narrative review	8
Headache Due to COVID‐19: A Disabling Combination	8
Cancer risk in patients with migraine: A population‐based cohort study in Denmark	8
The Influence of Photophobia on Postural Control in Patients With Migraine	8
Types of Triggers in Migraine – Factor Structure of the Headache Triggers Sensitivity and Avoidance Questionnaire and Development of a New Short Form (HTSAQ‐SF)	8
Ketamine‐Magnesium for Refractory Chronic Cluster Headache: A Case Series	8
Headache Virtual Visit Toolbox: The Transition From Bedside Manners to Webside Manners	8
Adverse childhood experiences and onset of migraine in Canadian adolescents: A cohort study	8
The unique role of stigma in migraine‐related disability and quality of life	8
Migraine treatment and COVID‐19 vaccines: No cause for concern	8
Open‐Label, Multi‐Dose, Pilot Safety Study of Injection of OnabotulinumtoxinA Toward the Otic Ganglion for the Treatment of Intractable Chronic Cluster Headache	8
Primary Empty Sella	8
Headache and systemic lupus erythematosus: A narrative review	8
Later high school start time is associated with lower migraine frequency in adolescents	8
Erenumab for migraine prevention in a patient with mitochondrial encephalopathy, lactate acidosis, and stroke‐like episodes syndrome: A case report	8
Different characteristics of cortical spreading depression in the sleep and wake states	8
Timing and durability of response to erenumab in patients with episodic migraine	8
Medication overuse headache in patients with chronic migraine using cannabis: A case–referent study	8
Acute and chronic management of posttraumatic headache in children: A systematic review	8
Primary headache disorders and body mass index categories: A systematic review and dose–response meta‐analysis	8
Shared biological foundations of post‐traumatic headache and migraine	8
Symptomatic migraine: A systematic review to establish a clinically important diagnostic entity	8
Intranasal ketamine for acute cluster headache attacks—Results from a proof‐of‐concept open‐label trial	8
A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene‐related peptide ligand (galcanezumab) or receptor (erenumab) ant	8
The role of artificial intelligence in headache medicine: Potential and peril	8
Alcohol as a trigger of migraine attacks in people with migraine. Results from a large prospective cohort study in English‐speaking countries	8
Cross‐Cultural Headache Care Within the United States: Speaking the Unspoken	8
Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine	8
Wildfire smoke exposure and emergency department visits for headache: A case‐crossover analysis in California, 2006–2020	8
Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses	8
Management of Spontaneous Intracranial Hypotension During Pregnancy: A Case Series	8
Impact of emergency department opioid use on future health resource utilization among patients with migraine	8
A pain in the ear: Two case reports of nervus intermedius neuralgia and narrative review	7
Music Modulates Awake Bruxism in Chronic Painful Temporomandibular Disorders	7
Regional cerebral perfusion during the premonitory phase of triggered migraine: A double‐blind randomized placebo‐controlled functional imaging study using pseudo‐continuous arterial spin labeling	7
Postural control impairment in patients with headaches—A systematic review and meta‐analysis	7
Spatial aspects of pain modulation are not disrupted in adolescents with migraine	7
Did she have an epidural? The long‐term consequences of postdural puncture headache and the role of unintended dural puncture	7
A narrative review of the importance of pharmacokinetics and drug–drug interactions of preventive therapies in migraine management	7
Introducing Headache’s “Trainee Highlights”	7
Treatment of medication overuse headache: Effect and predictors after 1 year—A randomized controlled trial	7
Cerebral Venous Thrombosis and Subdural Collection in a Comatose Patient: Do Not Forget Intracranial Hypotension. A Case Report	7
A prospective, randomized, double‐blind trial of intravenous chlorpromazine versus intravenous prochlorperazine for the treatment of acute migraine in adults presenting to the emergency department	7
Equity of African American Men in Headache in the United States: A Perspective From African American Headache Medicine Specialists (Part 2)	7
Gene polymorphism association studies in cluster headache: A field synopsis and systematic meta‐analyses	7
Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache	7
Headache in Medical Residents: A Cross‐Sectional Web‐Based Survey	7
Prolactin in headache and migraine: A systematic review of preclinical studies	7
Peripheral, Interictal Serum S100B Levels are Not Increased in Chronic Migraine Patients	7
	7
Readability Analysis of Online Headache and Migraine Information	7
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes	7
A Randomized Sham‐Controlled Cross‐Over Study on the Short‐Term Effect of Non‐Invasive Cervical Vagus Nerve Stimulation on Spinal and Supraspinal Nociception in Healthy Subjects	7